A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in subjects with advanced non–small cell lung cancer.

Category Primary study
JournalJ Clin Oncol.
Year 2014
This article has no abstract
Epistemonikos ID: 323f9c193732408ec7cad02444a26d47fae898af
First added on: Jun 11, 2020